Study Finds That ONGLYZA(TM) (saxagliptin) When Added to Metformin was Non-Inferior to JANUVIA (sitagliptin) When Added

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to develop and commercialize select investigational drugs for type 2 diabetes. These therapies address two key pathways in managing type 2 diabetes and seek to expand the range of current and future therapeutic options. Our collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of patients living with type 2 diabetes.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

ONGLYZA is a trademark of the Bristol-Myers Squibb Company.

JANUVIA is a trademark of Merck & Co. Inc.

Summary of Product Characteristics

ONGLYZA

See full prescribing information (http://www.makealias.com/just/SmPC.pdf )

CONTACTS: Media: Carmel Hogan, Bristol-Myers Squibb, +33-674-107-658, Carmel.hogan@bms.com; Ken Dominski, Bristol-Myers Squibb,+1-609-252-5251, Ken.dominski@bms.com; Neil McCrae, AstraZeneca, +44-207-304-5045, Neil.mccrae@astrazeneca.com; Christopher Sampson, AstraZeneca, +44-207-304-5130, Christopher.sampson@astrazeneca.com; Jim Minnick, AstraZeneca, +1-302-885-5135, jim.minnick@astrazeneca.com. Investors: John Elicker, Bristol-Myers Squibb, +1-609-252-4611, john.elicker@bms.com; Karl J. Hard, AstraZeneca, +44-207-304-5322, Karl.J.Hard@astrazeneca.com; Jonathan Hunt, AstraZeneca, +44-7775-704032, Jonathan.Hunt@astrazeneca.com; Edward Seage, AstraZeneca, +1-302-886-4065, Edward.Seage@astrazeneca.com; Jorgen Winroth, AstraZeneca, +1-212-579-0506, Jorgen.Winroth@astrazeneca.com